Capital International, Inc. Bio N Tech Se Transaction History

Capital International, Inc.

$7.23 Billion
Q2 2024

A detailed history of Capital International, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Capital International, Inc. holds 198,890 shares of BNTX stock, worth $23.6 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

198,890

Previous 11,833 1580.81%

Holding current value

$23.6 Million

Previous $1.09 Million 1364.89%

% of portfolio

0.22%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $15 Million - $19.2 Million	187,057 Added 1580.81%	198,890 $16 Million
Q1 2024 May 14, 2024	SELL	$88.96 - $112.35 $35,317 - $44,602	-397 Reduced 3.25%	11,833 $1.09 Million
Q4 2023 Feb 13, 2024	BUY	$90.91 - $112.75 $100,364 - $124,476	1,104 Added 9.92%	12,230 $1.29 Million
Q3 2023 Nov 13, 2023	BUY	$98.5 - $125.08 $146,568 - $186,119	1,488 Added 15.44%	11,126 $1.21 Million
Q2 2023 Aug 11, 2023	BUY	$102.58 - $129.66 $127,301 - $160,908	1,241 Added 14.78%	9,638 $1.04 Million
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $41,687 - $65,489	-352 Reduced 4.02%	8,397 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $1.12 Million - $1.6 Million	8,749 New	8,749 $1.18 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $1.77 Million - $3.25 Million	-14,036 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $1.36 Million - $2.94 Million	-6,582 Reduced 31.92%	14,036 $3.83 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $954,494 - $2.03 Million	8,423 Added 69.07%	20,618 $4.62 Million
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $1.05 Million - $1.46 Million	12,195 New	12,195 $1.33 Million

Others Institutions Holding BNTX

# of Institutions

328

Shares Held

40.6M

Call Options Held

845K

Put Options Held

1.23M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.

Account

Capital International, Inc. Bio N Tech Se Transaction History